FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy

Iranian Journal of Allergy, Asthma and Immunology

Volumn 10, Issue 3, 2011, Pages 155-161

  Mohajeri, Maryam ^a   Farazmand, Ali ^a   Bonab, Mandana Mohyeddin ^b   Nikbin, Behrooz ^b   Minagar, Alireza ^c  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Mesenchymal Stem Cells (MSC); Multiple Sclerosis (MS); T regulatory cells (Treg); Transcription factor (FOXP3)

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTICLE; BONE MARROW; CELL ISOLATION; CELL PROLIFERATION; CELL THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80053017817     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13):938-52.
2. Rocio S, Lopez D, Weiner HL. Novel therapeutic strategies for multiplesclerosis-a multifaceted adversary. Nat Rev Drug Discov 2008; 7(11):909-25.
3. Nikbin B, Mohyeddin Bonab M, Khosravi F, Talebian F. Role of B cells inpathogenesis of multiple sclerosis. Int Rev Neurobiol 2007; 79:13-42.
4. Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S, Abramsky O. Neuroprotection in multiple sclerosis. Clin Neurol Neurosurg 2006; 108(3):250-4.
5. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2(9):762-4.
6. Slavin S, Kurkalli BG, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 2008; 110(9):943-6.
7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4):315-7. (Pubitemid 44269669)
8. Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008; 65(6):753-61. (Pubitemid 351831453)
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science1999; 284(5411):143-7. (Pubitemid 29282067)
10. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival invivo. ExpHematol 2002; 30(1):42-8. (Pubitemid 34059216)
11. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe graftversus- hostdisease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363(9419):1439-41. (Pubitemid 38586721)
12. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development andfunction of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4(4):330-6. (Pubitemid 36432314)
13. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory Tcells in immunological selftolerance to self and non-self. Nat Immunol 2005; 6(4):345-52. (Pubitemid 41716771)
14. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineagespecification by the fork-head transcription factor FoxP3. Immunity 2005; 22(3):329-41. (Pubitemid 40387475)
15. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin inCD4+CD25+ T regulatory cells. Nat Immunol 2003; 4(4):337-42. (Pubitemid 36432315)
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development bythe transcription factor Foxp3. Science 2003; 299(5609):1057-61. (Pubitemid 36222930)
17. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factorFoxP3. Nat Immunol 2005; 6(4):331-7. (Pubitemid 41716769)
18. Chang X, Zheng P, Liu Y. FoxP3: A genetic link betweenimmunodeficiency and autoimmune diseases. Autoimmun Rev 2006; 5(6):399-402. (Pubitemid 44143032)
19. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, et al. DecreasedFOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81(1):45-52. (Pubitemid 41139109)
20. Hori S, Sakaguchi S: Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6(8):745-51. (Pubitemid 38781186)
21. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med 2004; 200(3):273-6. (Pubitemid 39031246)
22. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiplesclerosis. J Exp Med 2004; 199(7):971-9. (Pubitemid 38481088)
23. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+CD25+regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004; 199(9):1285-91. (Pubitemid 38620265)
24. Offner H, VandenbarkAA. Congruent effects of estrogen and T-cell receptorpeptide therapy on regulatory T cells in EAE and MS. Int Rev Immunol 2005; 24(5-6):447-77. (Pubitemid 41755156)
25. Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'hooghe MB, et al. Secondaryprogressive in contrast to relapsing-remitting multiple sclerosis patients showa normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83(8):1432-46. (Pubitemid 43844989)
26. Jane Hoyt Buckner: Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010; 10(12):849-859. doi:10.1038/nri2889.
27. Schneider A, Long SA, Kita M, Buckner JH: Persistence of FOXP3 expressionis impaired in RR-MS Treg. J Immunology 2009; 182:99.3.
28. Shi M, Liu ZW, Wang FS: Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 2011;164(1):1-8.
29. Zappia E, Casazza S, Pedemonte E, Federica Benvenuto F, Ivan Bonanni I,Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A:Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:5.
30. Bernardo ME, Avanzino MA, Perotti C, et al: Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. JCell Physiol 2007;211:121-30. (Pubitemid 46363901)
31. Maccario R, Podesta M, Moretta A, et al: Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favorsthe differentiation of CD4+T-cell subsets expressing a regulatory/suppressivephenotype. Haematologica 2005; 90:516-25. (Pubitemid 40592895)
32. Prevosto C, Zancolli M, Canevali P, et al: Generation of CD4+ or CD8+regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007; 92:881-8. (Pubitemid 350144234)
33. Batten P, Sarathchandra P, Antoniw JW, et al: Human mesenchymal stem cells induce T cell anergy and dowregulate T cell allo-responses via TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng 2006; 18:2263-73. (Pubitemid 44734984)
34. Mauro Di Ianni, Beatrice Del Papaa, Maria De Ioanni, Lorenzo Moretti, Elisabetta Bonifacioa, Debora Cecchini, 2008. Mesenchymal cells recruit and regulate T regulatory cells. Experimental Hematology 2008; 36: 309-18.
35. Shimon Slavin, Basan G.S. Kurkalli, Dimitrios, Karussis: The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders.clinical neurology and neurosurgery, 2008; 110: 943-6.